Base Therapeutics and KACTUS Announce Strategic Partnership with Synthego to Advance GMP AccuBase™ Base Editing Platform

Date: October 29, 2025– Zhuhai, China – Waltham, MA – Redwood City, CA

Base Therapeutics and KACTUS are excited to announce a strategic partnership with Synthego for the distribution of the AccuBase™ cytosine base editor. This collaboration aims to accelerate innovation and accessibility of next-generation cell and gene therapies.

This agreement integrates Base Therapeutics’ pioneering base-editing technologies, and KACTUS’ leadership in enzyme design and GMP-grade production with Synthego’s industry-leading RUO-to-GMP CRISPR Solutions to address unmet needs in the rapidly evolving field of genomic medicine.

“We are thrilled to collaborate with Synthego and Base Therapeutics to meet the needs of our global customers and accelerate the availability of therapeutic solutions for disease treatment. Through this alliance, we aim to advance the research and industrialization of cell and gene therapy,” said Edmund Wang, CEO of KACTUS.

Traditional CRISPR editing systems such as Cas9 or Cas12 rely on DNA double-strand breaks, introducing risks such as chromosomal loss or translocation. In contrast, the AccuBase™ cytosine base editor represents “CRISPR 2.0” technology that enables ultra-precise, cell-friendly editing with near-zero off-target effects. As the only GMP-grade base editing proteins currently available, AccuBase™ marks a new era for gene editing, shifting from “cutting” to “precision modification”.

“AccuBase™ is the next evolution of our clinical-grade solutions, complementing our best-in-class Guide RNA with a powerful base editing platform. With over five years of proven GMP experience and regulatory guidance, we are uniquely positioned to empower our therapeutic partners and accelerate their path to the clinic,” said Craig Christianson, CEO of Synthego.

 

“This partnership represents an important milestone in the global expansion of AccuBase™. We look forward to working with therapeutic partners to ensure that gene-editing technologies truly benefit human health worldwide,” said Dr. Tianhong Xu, Founder and CEO of Base Therapeutics.

As a leading supplier in cell and gene therapy, KACTUS provides an extensive portfolio of gene-editing enzymes—including GMP-grade Cas9 (FDA DMF filed) and GMP-grade AccuBase™—to support customers throughout the IND and clinical phases of drug development.

By integrating their respective scientific, commercial and regulatory strengths, this strategic partnership will advance the development of next-generation gene editing technologies, establishing a new standard for safe and effective tools in therapeutic applications.

About KACTUS

KACTUS is an innovation-driven company specializing in recombinant proteins and enzyme materials to support the development and manufacturing of biopharmaceuticals. Established in 2018, KACTUS has built deep expertise in protein R&D and production through its proprietary structure-designed protein platform, SAMS™. With its own 100,000 square foot GMP facility and certified quality system, KACTUS supplies a broad range of GMP-grade raw proteins and enzymes tailored to the needs of cell and gene therapy drug development.

About Synthego

Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies. Recognized in hundreds of peer-reviewed publications and trusted by thousands of researchers and therapeutic developers, Synthego is driving the future of medicine through cutting-edge genome-editing technologies.

About Base Therapeutics

Founded in 2021, Base Therapeutics is a high-tech enterprise focused on breakthrough innovations in gene editing. The company holds more than 30 domestic and international patents and is developing first-in-class cell and gene-editing products, particularly in cancer and rare genetic diseases. Its pipeline includes base-editing CAR-T and in vivo base-editing therapies, as well as NK510 and NK520 programs. Base Therapeutics’ NK cell base-editing therapies are already in clinical studies exploring efficacy and safety in relapsed, refractory, and metastatic solid and hematologic tumors where conventional chemotherapy has failed.